Pliant Therapeutics (PLRX) News Today → Did Intel Just Dethrone Nvidia? (From Chaikin Analytics) (Ad) Free PLRX Stock Alerts $14.14 +0.47 (+3.44%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 6:02 PM | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $13.67Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $13.67May 14 at 3:35 PM | msn.comPliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In PatientsMay 14 at 7:30 AM | globenewswire.comPliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary FibrosisMay 12 at 1:26 AM | americanbankingnews.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of "Buy" by BrokeragesMay 11 at 1:50 AM | americanbankingnews.comPliant Therapeutics, Inc. (NASDAQ:PLRX) to Post Q2 2024 Earnings of ($0.82) Per Share, HC Wainwright ForecastsMay 10, 2024 | marketbeat.comHC Wainwright Comments on Pliant Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:PLRX)Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) - HC Wainwright decreased their Q2 2024 earnings per share estimates for Pliant Therapeutics in a report released on Tuesday, May 7th. HC Wainwright analyst E. Arce now expects that the company will post earnings of ($0.82) per share for the qMay 9, 2024 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Pliant Therapeutics (NASDAQ:PLRX)May 9, 2024 | americanbankingnews.comPliant Therapeutics (NASDAQ:PLRX) PT Raised to $48.00May 9, 2024 | americanbankingnews.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Forecasted to Post Q2 2024 Earnings of ($0.81) Per ShareMay 9, 2024 | americanbankingnews.comPliant Therapeutics (NASDAQ:PLRX) Rating Reiterated by Needham & Company LLCMay 9, 2024 | americanbankingnews.comRoyal Bank of Canada Lowers Pliant Therapeutics (NASDAQ:PLRX) Price Target to $45.00May 9, 2024 | americanbankingnews.comCitigroup Lowers Pliant Therapeutics (NASDAQ:PLRX) Price Target to $44.00May 8, 2024 | markets.businessinsider.comPliant Therapeutics: Advancing Trials and Diversifying Pipeline Justify Buy RatingMay 8, 2024 | markets.businessinsider.comBuy Rating for Pliant Therapeutics: Promising Trials and Strategic Shifts Signal Growth PotentialMay 8, 2024 | finance.yahoo.comPliant Therapeutics First Quarter 2024 Earnings: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023)May 7, 2024 | markets.businessinsider.comBullish Outlook: Buy Rating on Pliant Therapeutics Amid Strong Clinical Trials and Solid FinancialsMay 7, 2024 | markets.businessinsider.comBuy Rating Justified by Pliant Therapeutics’ Promising Pipeline and Financial PrudenceMay 7, 2024 | msn.comThese Analysts Revise Their Forecasts On Pliant Therapeutics Following Q1 EarningsMay 7, 2024 | marketbeat.comCitigroup Trims Pliant Therapeutics (NASDAQ:PLRX) Target Price to $44.00Citigroup cut their price objective on Pliant Therapeutics from $45.00 to $44.00 and set a "buy" rating on the stock in a research report on Tuesday.May 7, 2024 | tmcnet.comPliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™May 7, 2024 | finance.yahoo.comPliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™May 7, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) PT Raised to $48.00 at OppenheimerOppenheimer raised their price target on shares of Pliant Therapeutics from $47.00 to $48.00 and gave the company an "outperform" rating in a report on Tuesday.May 7, 2024 | marketbeat.comPliant Therapeutics' (PLRX) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $36.00 price objective on shares of Pliant Therapeutics in a research report on Tuesday.May 6, 2024 | investorplace.comPLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q1 2024May 6, 2024 | globenewswire.comPliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 1, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Sees Large Volume IncreasePliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading VolumeMay 1, 2024 | globenewswire.comPliant Therapeutics to Participate in Upcoming Investor EventsApril 24, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Hits New 1-Year Low at $11.91Pliant Therapeutics (NASDAQ:PLRX) Reaches New 1-Year Low at $11.91April 10, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Stock Rating Reaffirmed by Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $38.00 target price on shares of Pliant Therapeutics in a research note on Wednesday.April 9, 2024 | investing.comPliant Therapeutics Inc (PLRX)April 9, 2024 | marketbeat.comVanguard Group Inc. Purchases 168,454 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)Vanguard Group Inc. boosted its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 6.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,945,312 shares of the company's stock after acquirApril 2, 2024 | globenewswire.comPliant Therapeutics to Participate in Upcoming Investor EventsMarch 27, 2024 | globenewswire.comPliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International ConferenceMarch 20, 2024 | marketbeat.comDeutsche Bank AG Has $17.09 Million Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)Deutsche Bank AG lessened its holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 23.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 985,569 shares of the company's stock after selling 305,083 shareMarch 17, 2024 | finance.yahoo.comPLRX Oct 2024 30.000 callMarch 16, 2024 | finance.yahoo.comPLRX Oct 2024 7.500 putMarch 12, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading VolumePliant Therapeutics (NASDAQ:PLRX) Sees Large Volume IncreaseMarch 12, 2024 | finanznachrichten.dePliant Therapeutics, Inc.: Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary FibrosisMarch 12, 2024 | globenewswire.comPliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary FibrosisMarch 11, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Trading Down 6.2%Pliant Therapeutics (NASDAQ:PLRX) Shares Down 6.2%March 11, 2024 | finance.yahoo.comPLRX Jul 2024 20.000 callMarch 8, 2024 | markets.businessinsider.comPliant Therapeutics: Strong Buy Rating on Promising Pipeline and Solid FinancialsMarch 6, 2024 | ca.finance.yahoo.comPLRX Jul 2024 10.000 putMarch 3, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Boosts Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX)Charles Schwab Investment Management Inc. lifted its stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 17.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 418,206 shares of the company's stock aMarch 1, 2024 | marketbeat.comHC Wainwright Comments on Pliant Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:PLRX)Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) - Research analysts at HC Wainwright lifted their Q1 2024 earnings per share estimates for Pliant Therapeutics in a report released on Wednesday, February 28th. HC Wainwright analyst E. Arce now expects that the company will post earnings of (February 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pliant Therapeutics Amid Promising Drug Pipeline and Financial StabilityFebruary 29, 2024 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Expected to Post FY2028 Earnings of $2.79 Per SharePliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) - Analysts at HC Wainwright raised their FY2028 earnings per share (EPS) estimates for shares of Pliant Therapeutics in a research note issued on Wednesday, February 28th. HC Wainwright analyst E. Arce now expects that the company will post eaFebruary 29, 2024 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Sold by Fmr LLCFmr LLC cut its stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 2.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,141,004 shares of the company's stock after selling 101,019 shareFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pliant Therapeutics on Promising Pipeline and Strong FinancialsFebruary 28, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $48.00 price target on shares of Pliant Therapeutics in a research note on Wednesday. Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address How to Make 100X on the AI Boom (Ad)For over four decades, Louis Navellier has found the very best tech stocks... Before the rest of the market. Click for his six specific AI stock in the crosshairs PLRX Media Mentions By Week PLRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PLRX News Sentiment▼0.150.57▲Average Medical News Sentiment PLRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PLRX Articles This Week▼253▲PLRX Articles Average Week Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TNGX News EOLS News LBPH News ZNTL News ALXO News SAGE News ETNB News PRAX News OPK News YMAB News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PLRX) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsAmerica’s worst nightmare?Porter & CompanyElon’s New Device is About to Shock the WorldInvestorPlaceClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap Sniper Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
